Vaccine · 2000
Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente.
Клиническое исследованиеСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Black S, Lieu T A, Ray G T, Capra A, Shinefield H R
Аннотация
OBJECTIVE: To review studies of the costs of pneumococcal disease and the cost effectiveness of pneumococcal conjugate vaccination conducted in association with the Kaiser Permanente Pneumococcal conjugate Efficacy Trial.
RESULTS: for each birth cohort of 3.8 million infants, routine pneumococcal conjugate vaccination program for healthy infants would prevent more than 12000 (78% of potential) meningitis and bacteremia cases, 53000 (69% of potential) pneumonia cases, and 1 million (8% of potential) otitis media episodes. Before accounting for vaccine costs, the vaccination program would reduce the costs of pneumococcal disease by $342 million in medical and $415 million in work-loss and other costs. Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose.
RESULTS: for each birth cohort of 3.8 million infants, routine pneumococcal conjugate vaccination program for healthy infants would prevent more than 12000 (78% of potential) meningitis and bacteremia cases, 53000 (69% of potential) pneumonia cases, and 1 million (8% of potential) otitis media episodes. Before accounting for vaccine costs, the vaccination program would reduce the costs of pneumococcal disease by $342 million in medical and $415 million in work-loss and other costs. Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose.
Предметные рубрики MeSH
AbsenteeismAnti-Bacterial AgentsBacteremiaChildChild, PreschoolCohort StudiesCost of IllnessCost-Benefit AnalysisCosts and Cost AnalysisDrug CostsHumansInfantInsurance BenefitsInsurance CarriersInsurance Claim ReviewInsurance, HealthMeningitis, PneumococcalMiddle Ear VentilationModels, TheoreticalOffice VisitsOtitis MediaOutcome and Process Assessment, Health CarePneumococcal InfectionsPneumococcal VaccinesPneumonia, PneumococcalRetrospective StudiesUnited StatesVaccinationVaccines, Conjugate